33
/it/
AIzaSyB4mHJ5NPEv-XzF7P6NDYXjlkCWaeKw5bc
November 1, 2025
2135661
178559
2
Create a timeline
Public Timelines
For educational institutions For teachers For students Cabinet
For educational institutions For teachers For students Open cabinet
FAQ Ricevere il Premium
Create a timeline
Public timelines
FAQ
About & FeedbackAccordoPrivatezzaFAQ
Support 24/7  
CabinetGet premium
Donate

10 magg 2013 anni - FDA responded to a petition and the original formulation of Opana ER (oxymorphone hydrochloride) Extended-Release Tablets was not withdrawn from the market for reasons of safety or effectiveness. As a result, generic versions of the original formulation can continue to be approved and marketed.

Aggiunto al nastro di tempo:

Opioids and the FDA

ByAnastasia
13 nov 2018
0
0
521

Data:

10 magg 2013 anni
Adesso
~ 12 years ago
About & FeedbackAccordoPrivatezzaFAQ
Support 24/7  
CabinetGet premium
Donate
The service accepts bank transfer (ACH, Wire) or cards (Visa, MasterCard, etc). Processed by Stripe.
Secured with SSL